Here we present a series of infiltrative ductal carcinoma breast cases (infiltrative ductal carcinoma with central necrosis) so closely mimicking 'DCIS with central comedo necrosis' that on initial morphological analysis these foci of tumors were labeled as DCIS (high grade, comedo). However on further histological work up and by using immunohistochemistry (IHC) for myoepithelial markers it was...

Breast hamartoma is an uncommon pathological entity. It is exceedingly rare to find ductal carcinoma in situ or invasive carcinoma within a breast hamartoma. We report one such case treated at our unit.

conclusion non-mass-like lesions, lesions with focal or segmental distribution, with a “plateau” enhancement curve type were the most frequent findings of dcis lesions on mri. background adequate diagnosis of ductal carcinoma in situ (dcis) could lead to efficacious treatment. due to the fact that dcis lesions can progress to invasive carcinomas and that the sensitivity of the standard examinat...

INTRODUCTION Intracystic papillary carcinoma represents a small distinctive subgroup of noninvasive breast cancer, accounts for <0.5% of breast malignancies and is extremely rare in men, it was originally reported as a localized non-invasive carcinoma, but is usually associated with ductal carcinoma in situ around the main tumor or invasive carcinoma. CASE PRESENTATION We report a case of 50-...

BACKGROUND p63 is a homologue of the p53 tumor suppressor gene and its protein is selectively expressed in the basal cells of a variety of epithelial tissues. It has recently been confirmed that p63 is expressed in the basal cells of normal prostate glands but not in prostatic carcinomas. Whether expression of p63 in breast correlates with tumor progression is the focus of this study. METHODS...

Ductal carcinoma in situ (DCIS) of the breast is becoming one of the most important diseases diagnosed in preventive medicine screening. The current age-adjusted incidence rate of DCIS is 32.5 per 100,000 women. For women 50–64 years of age, the incidence is approximately 88 per 100,000. Currently, for every 4 diagnoses of invasive breast cancer, there is 1 diagnosis of DCIS. Risk of DCIS is ra...

AIM This paper is a report of a descriptive qualitative study of the evolution of women's perceptions and experiences of ductal carcinoma in situ from the period near to diagnosis to 1 year later. BACKGROUND Ductal carcinoma in situ is a non-invasive breast condition where cancer cells are detected but confined to the ducts of the breast. With treatment, the condition has a positive prognosis...

In an original article published recently in The Breast, Galimberti et al, of the European Institute of Oncology in Milan, Italy, argue the reasons for adopting the IDN / ILN system nomenclature for carcinoma in situ in breast lesions. The term IDN (intraepithelial ductal neoplasia) was coined by Tavassoli in 1998 and shortly thereafter was proposed ILN (lobular intraepithelial neoplasia), as a...